Mario A. Cabrera-Salazar

Timing of Therapeutic Intervention Determines Functional and Survival Outcomes in a Mouse Model of Late Infantile Batten Disease

Mario A. Cabrera-Salazar, Eric M. Roskelley, Jie Bu et al. · Molecular Therapy · 2007 · 80 citations · Full text

Immunology, Cell Death, Immunotherapy +17

Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease

Mario A. Cabrera-Salazar, Matthew DeRiso, Scott D. Bercury et al. · PLoS ONE · 2012 · 78 citations · Full text

Pathology, Neurochemical Biomarkers, Substrate Reduction Therapy +22

Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease

Karen M. Ashe, Dinesh S. Bangari, Lingyun Li et al. · PLoS ONE · 2011 · 72 citations · Full text

Sandhoff Disease, Glycobiology, Immunology +17

Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy

Mario A. Cabrera-Salazar, Erin O’Rourke, Nadene Henderson et al. · Clinica Chimica Acta · 2004 · 62 citations

Gaucher Disease, Enzyme Replacement Therapy, Surrogate Markers +4

Gene therapy for the lysosomal storage disorders.

Mario A. Cabrera-Salazar, Enrico M. Novelli, John A. Barranger · PubMed · 2002 · 47 citations

Cell Therapy, In Vivo Gene Therapy, Genetics +17